文献速递呼吸道感染

阿米卡星脂质体吸入混悬液治疗难治性鸟分枝杆菌复合群肺病(CONVERT):前瞻性开放标签随机研究

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该研究纳入至少6个月稳定指南基础治疗(GBT)后痰培养仍MAC阳性的成人难治性MAC肺病患者,按2:1随机接受ALIS+GBT或单用GBT。第6个月时ALIS+GBT组培养转阴率29.0%(65/224),单用GBT组8.9%(10/112),OR 4.22(95%CI 2.08-8.57,P<0.001);严重治疗中出现不良事件发生率两组相近(20.2% vs 17.9%)。

要点

  • ALIS联合GBT显著提高难治性MAC肺病第6个月培养转阴率(29.0% vs 8.9%)。
  • ALIS+GBT组呼吸道不良事件更常见(87.4% vs 50.0%),以发声困难、咳嗽、呼吸困难为主。
  • 严重治疗中出现不良事件两组相近(20.2% vs 17.9%)。

核心结论

  • 在难治性MAC肺病患者中,ALIS联合GBT较单用GBT显著提高第6个月培养转阴率,严重不良事件发生率相近。

研究设计与样本

  • 前瞻性、开放标签、随机研究,纳入阿米卡星敏感且至少6个月稳定GBT后痰MAC仍阳性的成人MAC肺病患者。
  • 按2:1随机分为ALIS+GBT组(n=224)与单用GBT组(n=112)。
  • ALIS为每日一次吸入,单次药瓶向雾化器递送590 mg阿米卡星。
  • 主要终点为第6个月时连续3次每月痰MAC培养阴性的培养转阴。

主要发现

  • ALIS+GBT组65/224例(29.0%)达到培养转阴,单用GBT组10/112例(8.9%)达到(OR 4.22;95%CI 2.08-8.57;P<0.001)。
  • ALIS+GBT组较单用GBT组更可能达到转阴(HR 3.90;95%CI 2.00-7.60)。
  • 呼吸道不良事件(主要为发声困难、咳嗽、呼吸困难)发生率ALIS+GBT组87.4%、单用GBT组50.0%。
  • 严重治疗中出现不良事件发生率ALIS+GBT组20.2%、单用GBT组17.9%。
  • 入组患者平均年龄64.7岁,女性69.3%;多数有支气管扩张(62.5%)、慢阻肺(14.3%)或两者并存(11.9%)。

关键数值与推荐

  • 培养转阴定义为第6个月前连续3次每月痰MAC培养阴性。
  • ALIS每日一次,单次药瓶向雾化器递送590 mg阿米卡星。
  • 入组条件为阿米卡星敏感MAC肺病且至少6个月稳定GBT后痰MAC仍阳性。

临床怎么用

  • 对至少6个月稳定GBT后痰MAC仍阳性的难治性MAC肺病患者,可考虑在GBT基础上加用ALIS以提高第6个月培养转阴率。
  • 加用ALIS时需关注呼吸道不良事件(发声困难、咳嗽、呼吸困难),其发生率高于单用GBT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Improved therapeutic options are needed for patients with treatment-refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC). Objectives: To evaluate the efficacy and safety of daily amikacin liposome inhalation suspension (ALIS) added to standard guideline-based therapy (GBT) in patients with refractory MAC lung disease. Methods: Adults with amikacin-susceptible MAC lung disease and MAC-positive sputum cultures despite at least 6 months of stable GBT were randomly assigned (2:1) to receive ALIS with GBT (ALIS + GBT) or GBT alone. Once-daily ALIS was supplied in single-use vials delivering 590 mg amikacin to the nebulizer. The primary endpoint was culture conversion, defined as three consecutive monthly MAC-negative sputum cultures by Month 6. Measurements and Main Results: Enrolled patients (ALIS + GBT, n = 224; GBT-alone, n = 112) were a mean 64.7 years old and 69.3% female. Most had underlying bronchiectasis (62.5%), chronic obstructive pulmonary disease (14.3%), or both (11.9%). Culture conversion was achieved by 65 of 224 patients (29.0%) with ALIS + GBT and 10 of 112 (8.9%) with GBT alone (odds ratio, 4.22; 95% confidence interval, 2.08-8.57; P < 0.001). Patients in the ALIS + GBT arm versus GBT alone were more likely to achieve conversion (hazard ratio, 3.90; 95% confidence interval, 2.00-7.60). Respiratory adverse events (primarily dysphonia, cough, and dyspnea) were reported in 87.4% of patients receiving ALIS + GBT and 50.0% receiving GBT alone; serious treatment-emergent adverse events occurred in 20.2% and 17.9% of patients, respectively. Conclusions: Addition of ALIS to GBT for treatment-refractory MAC lung disease achieved significantly greater culture conversion by Month 6 than GBT alone, with comparable rates of serious adverse events. Clinical trial registered with www.clinicaltrials.gov (NCT02344004).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Griffith DE, Eagle G, Thomson R, et al. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018. PMID: 30216086. doi:10.1164/rccm.201807-1318OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。